HCM
GILD icon

Hollencrest Capital Management’s Gilead Sciences GILD Stock Holding History

Hollencrest Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94K Sell
744
-78
-9% -$10.3K 0.01% 457
2026
Q1 		$115K Buy
822
+21
+3% +$2.94K ﹤0.01% 401
2025
Q4 		$98.4K Buy
801
+80
+11% +$9.72K ﹤0.01% 451
2025
Q3 		$80K Hold
721
– – ﹤0.01% 470
2025
Q2 		$79.9K Sell
721
-610
-46% -$64.9K ﹤0.01% 428
2025
Q1 		$149K Sell
1,331
-3
-0.2% -$310 0.01% 318
2024
Q4 		$123K Hold
1,334
– – ﹤0.01% 369
2024
Q3 		$112K Buy
1,334
+3
+0.2% +$229 ﹤0.01% 367
2024
Q2 		$91.3K Hold
1,331
– – ﹤0.01% 409
2024
Q1 		$97.5K Hold
1,331
– – ﹤0.01% 369
2023
Q4 		$108K Buy
1,331
+502
+61% +$39.1K 0.01% 365
2023
Q3 		$62.1K Hold
829
– – 0.01% 439
2023
Q2 		$63.9K Hold
829
– – 0.01% 452
2023
Q1 		$68.8K Hold
829
– – 0.01% 427
2022
Q4 		$71.2K Buy
+829
New +$65.6K 0.01% 389
2022
Q1 		– Sell
-14,609
Closed -$1.06M – 382
2021
Q4 		$1.06M Buy
14,609
+1,300
+10% +$89.5K 0.08% 119
2021
Q3 		$929K Buy
+13,309
New +$935K 0.08% 125
2020
Q2 		– Sell
-12,597
Closed -$942K – 308
2020
Q1 		$942K Sell
12,597
-1,868
-13% -$129K 0.14% 97
2019
Q4 		$940K Buy
14,465
+3,100
+27% +$202K 0.11% 117
2019
Q3 		$720K Buy
11,365
+8,100
+248% +$529K 0.09% 135
2019
Q2 		$220K Hold
3,265
– – 0.03% 264
2019
Q1 		$212K Hold
3,265
– – 0.03% 259
2018
Q4 		$204K Hold
3,265
– – 0.03% 249
2018
Q3 		$212K Hold
3,265
– – 0.03% 259
2018
Q2 		$231K Hold
3,265
– – 0.03% 240
2018
Q1 		$246K Buy
3,265
+42
+1% +$3.34K 0.03% 236
2017
Q4 		$231K Sell
3,223
-5,800
-64% -$440K 0.03% 252
2017
Q3 		$731K Buy
9,023
+1,300
+17% +$99.4K 0.1% 132
2017
Q2 		$546K Hold
7,723
– – 0.08% 152
2017
Q1 		$525K Buy
7,723
+4,210
+120% +$296K 0.08% 172
2016
Q4 		$252K Sell
3,513
-730
-17% -$54.3K 0.04% 246
2016
Q3 		$336K Sell
4,243
-51
-1% -$4.14K 0.05% 229
2016
Q2 		$358K Sell
4,294
-4,394
-51% -$390K 0.06% 238
2016
Q1 		$798K Buy
8,688
+94
+1% +$8.48K 0.14% 125
2015
Q4 		$870K Sell
8,594
-1,430
-14% -$149K 0.15% 118
2015
Q3 		$984K Buy
10,024
+345
+4% +$38.3K 0.17% 102
2015
Q2 		$1.13M Sell
9,679
-2,003
-17% -$219K 0.16% 106
2015
Q1 		$1.15M Buy
11,682
+4,773
+69% +$485K 0.15% 108
2014
Q4 		$652K Buy
6,909
+1,532
+28% +$158K 0.09% 164
2014
Q3 		$572K Buy
5,377
+238
+5% +$23.3K 0.08% 171
2014
Q2 		$426K Buy
5,139
+1,332
+35% +$104K 0.06% 218
2014
Q1 		$270K Buy
3,807
+181
+5% +$14.2K 0.04% 289
2013
Q4 		$272K Buy
+3,626
New +$252K 0.04% 245

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hollencrest Capital Management's GILD Position: Q2 2026 in Review

Hollencrest Capital Management reduced its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, selling an estimated $10.3K and leaving 744 shares worth $94K. The position accounts for 0.01% of the portfolio, ranked #457.

Hollencrest Capital Management first reported a position in GILD in Q4 2013 and has held it in 43 quarters since. The position peaked at $1.15M in Q1 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Hollencrest Capital Management held 744 shares of Gilead Sciences worth $94K as of Q2 2026.
  • Hollencrest Capital Management sold 78 Gilead Sciences shares in Q2 2026, an estimated $10.3K.
  • Gilead Sciences made up 0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #457 holding.
  • Hollencrest Capital Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 43 quarters since.
  • Hollencrest Capital Management's Gilead Sciences position peaked at $1.15M in Q1 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.